Randomizated Open-label Control Trial to Evaluate if the Incorporation of sFlt1/PlGF Ratio in the Diagnosis and Classification of PE Improves Maternal and Perinatal Outcomes in Women With the Suspicion of the Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
With
Carlos III Health Institute
Spanish Clinical Research Network - SCReN
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Ability to read and understand informed consent.
Unique pregnancies.
\> 24 weeks and \<41 weeks
Suspected preeclampsia:
1. 140/90 or worsening of chronic hypertension
2. Onset of proteinuria (Labstick + or proteinuria\> 300mg / 24 hours) or worsening of it
3. Preeclampsia prodromal clinic such as epigastric, headache, photopsia, tinnitus and increased edema in the face hands or legs or weight gain (\> 1 kg per week in the third trimester)
4. Analytical alterations: decrease in platelets \<100,000. Increased transaminases.
5. Ultrasound alterations: Small fetus for gestational age or restriction of interatrial growth, increased resistance of the uterine arteries.
Pre-eclampsia (ACOG Practice Bulletin 2013)
You may not be if
Multiple pregnancies
\<24 weeks of gestation
Fetal chromosomal or congenital abnormalities
Conditions that require immediate delivery (eclampsia, pulmonary edema, uncontrolled hypertension, severe visual disturbances, severe headache, fetal demise, non-reassuring fetal status….)
Clareo Health | Randomizated Open-label Control Trial to Evaluate if the Incorporation of sFlt1/PlGF Ratio in the Diagnosis and Classification of PE Improves Maternal and Perinatal Outcomes in Women With the Suspicion of the Disease
